Gilead shares dip after warning about hepatitis C drug interaction

March 23, 2015 6:32 PM

5 0

(Reuters) - Gilead Sciences Inc shares slid 2 percent on Monday after the company warned about potentially fatal risks for patients being treated with its top-selling hepatitis c drugs who also take the potent heart drug amiodarone.

Gilead said it sent cautionary emails to healthcare providers on Friday to notify them of nine cases in which patients treated with its Harvoni or Sovaldi, while also taking amiodarone, suffered a slow heart beat condition known as symptomatic bradycardia. One of the patients died.

Read more

To category page

Loading...